Equities

Seikagaku Corp

4548:TYO

Seikagaku Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)810.00
  • Today's Change-7.00 / -0.86%
  • Shares traded36.20k
  • 1 Year change+7.14%
  • Beta0.5819
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments21,03128,77832,175
Total Receivables, Net8,2146,3355,865
Total Inventory9,3469,4708,586
Prepaid expenses------
Other current assets, total2,9552,1271,999
Total current assets41,54646,71048,625
Property, plant & equipment, net15,21911,32510,021
Goodwill, net2,1072,0942,093
Intangibles, net1,0931,137834
Long term investments18,79013,23212,733
Note receivable - long term------
Other long term assets1,272274252
Total assets81,79575,62575,244
LIABILITIES
Accounts payable1,652879680
Accrued expenses676624654
Notes payable/short-term debt300300300
Current portion long-term debt/capital leases3537175
Other current liabilities, total4,5354,8595,724
Total current liabilities7,1986,6997,533
Total long term debt615258
Total debt396389533
Deferred income tax2,1081,5131,168
Minority interest------
Other liabilities, total146145145
Total liabilities9,5138,4098,904
SHAREHOLDERS EQUITY
Common stock3,8403,8403,840
Additional paid-in capital5,3015,3015,301
Retained earnings (accumulated deficit)54,73853,97553,305
Treasury stock - common(2259)(2279)(802)
Unrealized gain (loss)5,5263,0333,212
Other equity, total5,1363,3461,484
Total equity72,28267,21666,340
Total liabilities & shareholders' equity81,79575,62575,244
Total common shares outstanding555556
Treasury shares - common primary issue2.252.270.57
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.